Key trends and strategic issues shaping the industry

Datamonitor has identified the key trends and events that impacted the pharmaceutical market on a macro-environmental and corporate strategy level in 2006. These range from the continuation of long term trends such as the focus on cost containment to more recent impacts such as the effects of Medicare Part D and the increasing power of the Democratic part in the US.

To overcome the poor R&D productivity that has characterized the pharmaceutical industry over the last few years, companies are being forced to re-evaluate R&D strategies. Companies are continuing to use licensing and acquisitions along with better prioritised spending and more structured decision making in an effort to deliver improved returns.

Pharma companies turned to a range of inorganic growth strategies in 2006 to improve sales and profit. This has allowed branded companies to expand their geographical presence, while enhancing the strength of their pipelines, frequently with the acquisition of small Pharma and biotechs providing additional products and supplementary technologies.

The role of emerging markets in the pharmaceutical industry is changing: not only do markets such as India and China represent significant targets for growth because of their rapid economic expansion, but with the globalization of the industry, manufacturers are increasingly outsourcing and offshoring numerous functions there.

Read more...

• Authorized Generic Pharmaceuticals (29/06/2010)
• Melanoma (23/06/2010)
• Drug Repositioning & R&D Enhancement (07/06/2010)

• Esophageal Cancer (26/05/2008)
• SCLC and Malignant Mesothelioma (26/05/2008)
• SEO for Pharma (25/05/2008)
• Atopic Dermatitis (21/05/2008)
• ePrescribing (21/05/2008)
• Depression (21/05/2008)
• Nosocomial Infections (21/05/2008)
• Asthma Phenotypes (21/05/2008)
• Multiple Sclerosis (21/05/2008)

---